EXACT Sciences (NASDAQ:EXAS)‘s stock had its “buy” rating reissued by equities research analysts at Stifel Nicolaus in a research report issued to clients and investors on Friday, TipRanks reports. They currently have a $110.00 price objective on the medical research company’s stock. Stifel Nicolaus’ price target suggests a potential upside of 12.04% from the company’s previous close.
Several other research analysts have also weighed in on the company. BidaskClub raised EXACT Sciences from a “hold” rating to a “buy” rating in a research report on Tuesday, February 4th. Jefferies Financial Group decreased their target price on EXACT Sciences from $138.00 to $120.00 and set a “buy” rating on the stock in a report on Wednesday, October 30th. Leerink Swann decreased their target price on EXACT Sciences from $133.00 to $105.00 and set an “outperform” rating on the stock in a report on Wednesday, October 30th. Citigroup started coverage on EXACT Sciences in a report on Monday, January 6th. They set a “buy” rating and a $120.00 target price on the stock. Finally, ValuEngine raised EXACT Sciences from a “hold” rating to a “buy” rating in a report on Saturday. One research analyst has rated the stock with a hold rating and eighteen have given a buy rating to the stock. EXACT Sciences currently has a consensus rating of “Buy” and an average price target of $121.00.
NASDAQ:EXAS opened at $98.18 on Friday. The firm has a market capitalization of $12.58 billion, a price-to-earnings ratio of -57.41 and a beta of 1.36. EXACT Sciences has a twelve month low of $75.35 and a twelve month high of $123.99. The stock’s 50 day moving average price is $94.13 and its two-hundred day moving average price is $97.43. The company has a quick ratio of 2.63, a current ratio of 2.75 and a debt-to-equity ratio of 0.67.
EXACT Sciences (NASDAQ:EXAS) last posted its quarterly earnings results on Tuesday, February 11th. The medical research company reported $0.54 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.37) by $0.91. The firm had revenue of $295.58 million for the quarter, compared to analyst estimates of $294.39 million. EXACT Sciences had a negative return on equity of 29.06% and a negative net margin of 29.83%. As a group, analysts anticipate that EXACT Sciences will post -1.64 earnings per share for the current year.
In related news, insider G Bradley Cole sold 10,000 shares of the business’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $90.30, for a total transaction of $903,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 2.20% of the stock is currently owned by insiders.
Hedge funds have recently bought and sold shares of the stock. Valeo Financial Advisors LLC boosted its stake in EXACT Sciences by 154.6% in the 4th quarter. Valeo Financial Advisors LLC now owns 443 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 269 shares during the period. Steward Partners Investment Advisory LLC increased its holdings in EXACT Sciences by 129.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 497 shares of the medical research company’s stock worth $45,000 after purchasing an additional 280 shares in the last quarter. Shine Investment Advisory Services Inc. increased its holdings in EXACT Sciences by 31.8% in the 3rd quarter. Shine Investment Advisory Services Inc. now owns 518 shares of the medical research company’s stock worth $47,000 after purchasing an additional 125 shares in the last quarter. Coastal Investment Advisors Inc. increased its holdings in EXACT Sciences by 65.7% in the 3rd quarter. Coastal Investment Advisors Inc. now owns 648 shares of the medical research company’s stock worth $59,000 after purchasing an additional 257 shares in the last quarter. Finally, Bridger Capital Management LLC acquired a new position in EXACT Sciences in the 3rd quarter worth about $68,000. 87.01% of the stock is currently owned by institutional investors and hedge funds.
About EXACT Sciences
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.
Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.